A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Latest Information Update: 02 Apr 2025
At a glance
- Drugs NCE 401 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Biliary cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms KEYNOTE-E34
- Sponsors TiumBio
- 13 Feb 2025 Planned number of patients changed from 142 to 140.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2024 According to a TiumBio Media Release, interim results from the Phase 1b presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.